The federal government has cancelled a deal with vaccine maker Novavax to manufacture COVID-19 vaccine in Montreal, the company said in a filing with the U.S. securities regulator.

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

Although Novavax secured the FDA’s authorization for an updated version of its protein-based COVID-19 vaccine toward the end of August, it was delayed compared to the approvals/authorizations ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker. The COVID-19 vaccine company, based in Maryland ...